Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | PDE5A | O76074 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5196887 | 0.85 | PDE5A (0.42) | ALDH1A1HPGDPDE5AKDM4ENPC1 | |
| SCHEMBL4896885 | 0.80 | KDM4E (0.47) | ALDH1A1HPGDKDM4ERPA1NR4A1 | |
| SCHEMBL1900992 | 0.76 | PDE5A (0.70) | ALDH1A1HPGDPDE5AKDM4ENPC1 | |
| SCHEMBL3073752 | 0.71 | PDE5A (0.73) | ALDH1A1HPGDPDE5AKDM4ENPC1 | |
| SCHEMBL7494265 | 0.71 | PDE5A (0.73) | ALDH1A1HPGDPDE5AKDM4ENPC1 | |
| SCHEMBL4894995 | 0.71 | JAK2 (0.48) | ALDH1A1HPGDKDM4ETP53MAPT | |
| SCHEMBL2661760 | 0.70 | CNR1 (0.45) | MAPTMAPK1SMN1; SMN2CNR1ACHE | |
| SCHEMBL958473 | 0.70 | CNR1 (0.58) | ALDH1A1HPGDPDE5AKDM4ENPC1 | |
| SCHEMBL3205814 | 0.70 | PDE5A (0.64) | ALDH1A1HPGDPDE5AKDM4ENPC1 | |
| SCHEMBL3239696 | 0.70 | PDE5A (0.52) | ALDH1A1HPGDPDE5AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | claimed |
| EP-1802583-A1 | HETEROCYCLIC CARBONYL COMPOUNDS | Merck Patent GmbH (DE) | 2007-07-04 | — | — | EP | claimed |
| WO-2006045350-A1 | HETEROCYCLIC CARBONYL COMPOUNDS | MERCK PATENT GMBH (DE) | 2006-05-04 | — | — | WO | claimed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| EP-1802583-A1 | HETEROCYCLIC CARBONYL COMPOUNDS | Merck Patent GmbH (DE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006045350-A1 | HETEROCYCLIC CARBONYL COMPOUNDS | MERCK PATENT GMBH (DE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | SGK1, SGK2, SGK3 | ALDH1A1 3961/4885HPGD 1322/4885PDE5A 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.